Therapeutic targeting of molecules involved in leukocyte-endothelial cell interactions

FEBS Journal

Volumn 273, Issue 19, 2006, Pages 4416-4424

  Kaneider, Nicole C ^a   Leger, Andrew J ^a,b   Kuliopulos, Athan ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Endothelium; Inflammatory diseases; Leukocytes; Therapeutic targets

Indexed keywords

1 (2 BROMOPHENYL) 3 (2 HYDROXY 4 NITROPHENYL)UREA; 1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; 4 [3 [4 (3,4 DICHLOROBENZYL) 2 MORPHOLINYLMETHYL]UREIDOMETHYL]BENZAMIDE; ALICAFORSEN; ANTIINFLAMMATORY AGENT; BERTILIMUMAB; BIMOSIAMOSE; CDP 850; CTCE 9908; CY 1503; CY 1747; EFALIZUMAB; ERLIZUMAB; FINGOLIMOD; G PROTEIN COUPLED RECEPTOR; INCB 3284; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; MARAVIROC; MLN 02; MONTELUKAST; NATALIZUMAB; OC 229648; P SELECTIN GLYCOPROTEIN LIGAND 1; PRANLUKAST; REPERTAXIN; ROVELIZUMAB; SB 332235; SELECTIN; TR 14035; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZAFIRLUKAST;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLERGIC ASTHMA; ANTIINFLAMMATORY ACTIVITY; ASTHMA; ATOPIC DERMATITIS; CELL INTERACTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMPETITIVE INHIBITION; CROHN DISEASE; DIABETES MELLITUS; DISEASE COURSE; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIUM CELL; ENTERITIS; GRAFT REJECTION; HEART INFARCTION; HUMAN; IMMUNE SYSTEM; INFLAMMATORY DISEASE; INSULIN RESISTANCE; LEUKOCYTE; LYMPHOCYTE; MACROPHAGE; MONOCYTE; MULTIPLE SCLEROSIS; NEUTROPHIL; NONHUMAN; PERITONITIS; PRIORITY JOURNAL; PROSTATE CANCER; PSORIASIS; REPERFUSION INJURY; RHEUMATOID ARTHRITIS; SHORT SURVEY; STROKE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; ULCERATIVE COLITIS;

ANIMALS; CELL COMMUNICATION; ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; INTEGRINS; LEUKOCYTES; RECEPTORS, G-PROTEIN-COUPLED; SELECTINS;

EID: 33748753745     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2006.05441.x     Document Type: Short Survey

References (46)

1. Xie H, Lim YC, Luscinskas FW & Lichtman AH (1999) Acquisition of selectin binding and peripheral homing properties by CD4(+) and CD8(+) T cells. J Exp Med 189, 1765-1776.
2. Weninger W, Crowley MA, Manjunath N & von Andrian UH (2001) Migratory properties of naive, effector, and memory CD8(+) T cells. J Exp Med 194, 953-966.
3. Berland R & Wortis HH (2002) Origins and functions of B-1 cells with notes on the role of CD5. Annu Rev Immunol 20, 253-300.
4. Herzenberg LA (2000) B-1 cells: the lineage question revisited. Immunol Rev 175, 9-22.
5. MacConmara M & Lederer JA (2005) B cells. Crit Care Med 33, S514-S516.
6. Ulbrich H, Eriksson EE & Lindbom L (2003) Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease. Trends Pharmacol Sci 24, 640-647.
7. Yanofsky SD, Baldwin DN, Butler JH, Holden FR, Jacobs JW, Balasubramanian P, Chinn JP, Cwirla SE, Peters-Bhatt E, Whitehorn EA et al. (1996) High affinity type I interleukin 1 receptor antagonists discovered by screening recombinant peptide libraries. Proc Natl Acad Sci USA 93, 7381-7386.
8. Macias I, Garcia-Perez S, Ruiz-Tudela M, Medina F, Chozas N & Giron-Gonzalez JA (2005) Modification of pro- and antiinflammatory cytokines and vascularrelated molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis. J Rheumatol 32, 2102-2108.
9. Pitzalis C, Pipitone N & Perretti M (2002) Regulation of leukocyte-endothelial interactions by glucocorticoids. Ann N Y Acad Sci 966, 108-118.
10. Sanchez-Madrid F & Gonzalez-Amaro R (2001) Drugs, inflammation and cell adhesion receptors. Expert Opin Pharmacother 2, 3-17.
11. Sukhova GK, Williams JK & Libby P (2002) Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol 22, 1452-1458.
12. McEver RP (2002) Selectins: lectins that initiate cell adhesion under flow. Curr Opin Cell Biol 14, 581-586.
13. Ley K (2001) Functions of selectins. Results Probl Cell Differ 33, 177-200.
14. Mocco J, Choudhri T, Huang J, Harfeldt E, Efros L, Klingbeil C, Vexler V, Hall W, Zhang Y, Mack W et al. (2002) HuEP5C7 as a humanized monoclonal anti-E/P-selectin neurovascular protective strategy in a blinded placebo-controlled trial of nonhuman primate stroke. Circ Res 91, 907-914.
15. Xia L, Sperandio M, Yago T, McDaniel JM, Cummings RD, Pearson-White S, Ley K & McEver RP (2002) P-selectin glycoprotein ligand-1-deficient mice have impaired leukocyte tethering to E-selectin under flow. J Clin Invest 109, 939-950.
16. Kaila N & Thomas BET (2002) Design and synthesis of sialyl Lewis (x) mimics as E- and P-selectin inhibitors. Med Res Rev 22, 566-601.
17. Friedrich M, Bock D, Philipp S, Ludwig N, Sabat R, Wolk K, Schroeter-Maas S, Aydt E, Kang S, Dam TN et al. (2006) Pan-selectin antagonism improves psoriasis manifestation in mice and man. Arch Dermatol Res 297, 345-351.
18. Beeh KM, Beier J, Meyer M, Buhl R, Zahlten R & Wolff G (2005) Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: A randomized, double-blind, placebocontrolled clinical cross-over-trial. Pulm Pharmacol Ther 19, 233-241.
19. Wienrich BG, Krahn T, Schon M, Rodriguez ML, Kramer B, Busemann M, Boehncke WH & Schon MP (2006) Structure-function relation of efomycines, a family of small-molecule inhibitors of selectin functions. J Invest Dermatol 126, 882-889.
20. Shimaoka M & Springer TA (2003) Therapeutic antagonists and conformational regulation of integrin function. Nat Rev Drug Discov 2, 703-716.
21. Hynes RO (1992) Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69, 11-25.
22. Faxon DP, Gibbons RJ, Chronos NA, Gurbel PA & Sheehan F (2002) The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. J Am Coll Cardiol 40, 1199-1204.
23. Baran KW, Nguyen M, McKendall GR, Lambrew CT, Dykstra G, Palmeri ST, Gibbons RJ, Borzak S, Sobel BE, Gourlay SG et al. (2001) Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study. Circulation 104, 2778-2783.
24. Sherman D, the Enlimomab Acute Stroke Trial Investigators (2001) Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology 57, 1428-1434.
25. Ohmura T, Konomi A, Satoh Y, Hayashi T, Tsunenari I, Kadota T, Panzenbeck MJ & Satoh H (2004) Suppression of atopic-like dermatitis by treatment with antibody to lymphocyte function-associated antigen-1 in NC/Nga mouse. Eur J Pharmacol 504, 113-117.
26. Joshi A, Bauer R, Kuebler P, White M, Leddy C, Compton P, Garovoy M, Kwon P, Walicke P & Dedrick R (2006) An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis. J Clin Pharmacol 46, 10-20.
27. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, Willmer-Hulme AJ, Dalton CM, Miszkiel KA & O'Connor PW (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348, 15-23.
28. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnalek P, Zadorova Z, Palmer T & Donoghue S (2003) Natalizumab for active Crohn's disease. N Engl J Med 348, 24-32.
29. Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JW, Dube R, Cohen A, Steinhart AH, Landau S et al. (2005) Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 352, 2499-2507.
30. White JR, Lee JM, Young PR, Hertzberg RP, Jurewicz AJ, Chaikin MA, Widdowson K, Foley JJ, Martin LD, Griswold DE et al. (1998) Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem 273, 10095-10098.
31. Sekido N, Mukaida N, Harada A, Nakanishi I, Watanabe Y & Matsushima K (1993) Prevention of lung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8. Nature 365, 654-657.
32. Bertini R, Allegretti M, Bizzarri C, Moriconi A, Locati M, Zampella G, Cervellera MN, Di Cioccio V, Cesta MC, Galliera E et al. (2004) Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci USA 101, 11791-11796.
33. Kaneider NC, Agarwal A, Leger AJ & Kuliopulos A (2005) Reversing systemic inflammatory response syndrome with chemokine receptor pepducins. Nat Med 11, 661-665.
34. Trebst C, Sorensen TL, Kivisakk P, Cathcart MK, Hesselgesser J, Horuk R, Sellebjerg F, Lassmann H & Ransohoff RM (2001) CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am J Pathol 159, 1701-1710.
35. Horuk R, Shurey S, Ng HP, May K, Bauman JG, Islam I, Ghannam A, Buckman B, Wei GP, Xu W et al. (2001) CCR1-specific non-peptide antagonist: efficacy in a rabbit allograft rejection model. Immunol Lett 76, 193-201.
36. Horuk R, Clayberger C, Krensky AM, Wang Z, Grone HJ, Weber C, Weber KS, Nelson PJ, May K, Rosser M et al. (2001) A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection. J Biol Chem 276, 4199-4204.
37. White JR, Lee JM, Dede K, Imburgia CS, Jurewicz AJ, Chan G, Fornwald JA, Dhanak D, Christmann LT, Darcy MG et al. (2000) Identification of potent, selective non-peptide CC chemokine receptor-3 antagonist that inhibits eotaxin-, eotaxin-2-, and monocyte chemotactic protein-4-induced eosinophil migration. J Biol Chem 275, 36626-36631.
38. Luster AD, Alon R & von Andrian UH (2005) Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol 6, 1182-1190.
39. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P et al. (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277, 21453-21457.
40. Muller H, Hofer S, Kaneider N, Neuwirt H, Mosheimer B, Mayer G, Konwalinka G, Heufler C & Tiefenthaler M (2005) The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. Eur J Immunol 35, 533-545.
41. Kaneider NC, Lindner J, Feistritzer C, Sturn DH, Mosheimer BA, Djanani AM & Wiedermann CJ (2004) The immune modulator FTY720 targets sphingosine-kinase-dependent migration of human monocytes in response to amyloid beta-protein and its precursor. Faseb J 18, 1309-1311.
42. Seeley S, Covic L, Jacques SL, Sudmeier J, Baleja JD & Kuliopulos A (2003) Structural basis for thrombin activation of a protease-activated receptor: inhibition of intramolecular liganding. Chem Biol 10, 1033-1041.
43. Covic L, Gresser AL, Talavera J, Swift S & Kuliopulos A (2002) Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proc Natl Acad Sci USA 99, 643-648.
44. Covic L, Misra M, Badar J, Singh C & Kuliopulos A (2002) Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med 8, 1161-1165.
45. Boire ACL, Agarwal A, Jaques S, Sherifi S & Kuliopulos A (2005) PAR1 is a Matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120, 303-313.
46. Leger AJ, Jaques SL, Badar J, Kaneider NC, Derian CK, Andrade-Gordon P, Covic L & Kuliopulos A (2006) Blocking the protease-activated receptor 1-4 heteroddimer in platelet-mediated thrombosis. Circulation 113, 1244-1254.